Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

On-Demand e-Posters Display

155P - Surufatinib plus toripalimab for 2L treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase 2 study

Date

09 Dec 2021

Session

On-Demand e-Posters Display

Presenters

Ming Lu

Citation

Annals of Oncology (2021) 32 (suppl_7): S1428-S1457. 10.1016/annonc/annonc787

Authors

M. Lu1, X. Yu2, Z. Chen3, Y. Zhang4, Z. Li5, X. Zhang6, F. Yin7, F. Ye8, Y. Cheng9, L. Song10, J. Xu11, J. Zhou12, H. Shi12, P. Tan12, S. Fan12, W. Su12, L. Shen13

Author affiliations

  • 1 Peking University Cancer Hospital & Institute, 100000 - Beijing/CN
  • 2 Fudan University Shanghai Cancer Center, Shanghai/CN
  • 3 The Second Hospital of Anhui Medical University, Heifei/CN
  • 4 Harbin Medical University Cancer Hospital, Harbin/CN
  • 5 West China Hospital of Sichuan University, Chengdu/CN
  • 6 Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou/CN
  • 7 The Fourth Hospital of Hebei Medical University, Shijiazhuang/CN
  • 8 The First Affiliated Hospital of Xiamen University, Xiamen/CN
  • 9 Jilin Cancer Hospital, Chaoyang Borough, 130021 - Changchun/CN
  • 10 The First Affiliated Hospital of Zhengzhou University, Zhengzhou/CN
  • 11 The Fifth Medical Center, General Hospital of the People's Liberation Army, Beijing/CN
  • 12 HUTCHMED, Shanghai/CN
  • 13 Peking University Cancer Hospital & Institute, Beijing/CN
More

Abstract 155P

Background

Surufatinib (S, a small-molecule inhibitor of VEGFR1-3, FGFR1 and CSF-1R) plus toripalimab (T, an anti-PD-1 antibody) showed encouraging antitumor activity in solid tumors. Here, we report the results of 3 cohorts of advanced G/GEJ adenocarcinoma, ESCC and NEC of an ongoing, multi-cohort, phase 2 study of S + T (NCT04169672).

Methods

Patients (pts) with histologically confirmed G/GEJ adenocarcinoma or advanced/metastatic ESCC or advanced NEC who progressed after 1L systemic chemotherapy were enrolled in cohorts A, B, C, respectively. Eligible pts received 21-day cycles of S (250 mg orally QD) plus T (240 mg IV, Q3W). The primary endpoint was objective response rate (ORR) per RECIST 1.1.

Results

Sixty-two pts were enrolled, 21, 20, 21 in cohorts A, B, C, respectively. At data cutoff (Aug 1, 2021), 61 pts (20, 20, 21 in cohorts A, B, C) had at least one post baseline tumor assessment; of them, the confirmed ORR (95%CI) were 30% (11.89-54.28), 30% (11.89-54.28), 23.8% (8.22-47.17) in cohorts A, B, C, respectively, and DCR (95%CI) were 80% (56.34-94.27), 60% (36.05-80.88), 71.4% (47.82-88.72). Median PFS (mPFS) (95%CI): 4.11 mo (2.60-6.90), 2.73 mo (1.25-5.45) and 4.14 mo (1.45-5.45); median OS: not reached (median duration of follow up, 10.09 mo), 9.72 mo (7.79-NR) and 10.87 mo (9.07-NR), respectively. In subgroups of PD-L1 positive pts, in cohort A (defined CPS ≥1), cohorts B and C (CPS ≥5), respectively, the confirmed ORR: 37.5% (15.20-64.57) in 16 pts, 38.5% (13.86-68.42) in 13 pts and 22.2% (2.81-60.01) in 9 pts; mPFS: 4.50 mo (2.60-7.59), 4.27 mo (1.25-5.72) and 5.32 mo (1.18-11.50), respectively. In overall pts (n=62), 27 (43.5%) pts reported G≥3 TRAEs, most commonly (≥3 pts) with neutrophil count decreased, WBC decreased, anemia, hypertension (4 [6.5%], each); and hypertriglyceridemia, hyperglycemia (3 [4.8%], each). Two (3.2%) pts had TRAEs led to treatment discontinuation or death.

Conclusions

S + T exhibited promising efficacy and manageable toxicity in pts with previously treated advanced G/GEJ adenocarcinoma, ESCC and NEC, especially for PD-L1 positive pts.

Clinical trial identification

NCT04169672.

Editorial acknowledgement

We thank Xia Yin (medical writer of HUTCHMED) for the abstract editing work.

Legal entity responsible for the study

HUTCHMED.

Funding

HUTCHMED.

Disclosure

J. Zhou, H. Shi, P. Tan, S. Fan, W. Su: Financial Interests, Personal, Full or part-time Employment: HUTCHMED. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.